October Newsletter

Details of the Golden Helix CancerKB Database Update 

Details of the Golden Helix CancerKB Database Update

By Julia Love
Genomic Curator and Product Quality Specialist

For those who may be unfamiliar with the Golden Helix CancerKB source, it is a professional curated set of interpretations for the most common biomarkers and cancer genes. More specifically, users can incorporate report-ready gene descriptions, tumor-specific outcomes and frequencies, and biomarker summaries. Even more, for the most common biomarkers ... Read More

Reviewing Clinical Studies for Novel Splice Variants in VSClinical

Reviewing Clinical Studies for Novel Splice Variants in VSClinical

By Nathan Fortier
Director of Research

In order to thoroughly assess a variant’s pathogenicity, it is important to take into account the variant’s effect on splicing. While the interpretation of variants that disrupt the pairs of bases at the beginning of a splice site is fairly straightforward, variants resulting in the introduction of a novel splice site are more difficult to interpret. In this blog post, we will discuss VarSeq’s capabilities...Read More

2021 Golden Helix End of Year Packages

2021 End of Year Pricing Packages

By Delaina Hawkins
Senior Director of Operations & Marketing

We want to express our gratitude to all of our customers for their support with a promise not to increase prices in 2021. This is also a gesture we would like to extend to potential customers who are considering Golden Helix solutions through the variety of pricing packages that we have designed... Read More

 

 

CEO Corner
New eBook: Clinical Variant Analysis for Cancer

Our November webcast will be focusing on our cancer-specific knowledgebase, CancerKB. Our team has made significant investments into this knowledgebase to ensure we provide our customers with clinical assessments that can streamline cancer-related variant diagnostics. This is in line with our overarching thesis behind VSClinical which is to streamline the clinical variant interpretation and ensure high-quality clinical reports. We hope you all enjoy the upcoming discussion on this topic.

Upcoming Webcast

Using Golden Helix CancerKB to Accelerate NGS Cancer Testing

Nov. 17, 2021, 12pm EDT

Presented by Julia Love, Genomic Curator and Product Quality Specialist

This webcast will deomnstrate the application of CancerKB and how easy somatic variant analysis can
be in VSClinical. Namely, I will deep dive into the following topics:

  • The process our expert curators use to produce high-quality cancer 
    interpretations
  • Examples of complex biomarker interpretations simplified using CancerKB
  • Report content filled in by CancerKB even fore rare genes
  • Integrating customer feedback and the future of CancerKB
Save Your Seat
Customer Success

Congratulations to all of our customers who have published this month! To highlight just a few:

Comprehensive phenotypic and functional analysis of dominant and recessive FOXE3 alleles in ocular developmental disorders - Linda Reis & colleagues, Medical College of Wisconsin / Published in Human Molecular Genetics

Genome-wide association study and population structure analysis of seed-bound amino acids and total protein in watermelon - Umesh Reddy & colleagues, West Virginia State University / Published in PeerJ

About Golden Helix

Golden Helix has been delivering industry-leading bioinformatics solutions for the advancement of life science research and translational medicine for over 20 years with 1,000s of users around the world. Their innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from NGS sequencers and microarrays. With their solutions, hundreds of the world's top hospitals, testing labs, pharmaceutical, biotech, and academic research organizations can harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine.